|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
KR20140070676A
(ko)
|
2002-09-06 |
2014-06-10 |
인설트 테라페틱스, 인코퍼레이티드 |
공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
ES2423060T3
(es)
*
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
WO2006017932A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
CA2580707C
(en)
|
2004-09-24 |
2014-07-08 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of apob and uses thereof
|
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
|
EA017847B1
(ru)
|
2005-01-07 |
2013-03-29 |
Элнилэм Фармасьютикалз, Инк. |
Композиция для лечения респираторных синцитиальных вирусов
|
|
WO2006081192A2
(en)
*
|
2005-01-24 |
2006-08-03 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the nogo-l or nogo-r gene and uses thereof
|
|
PL1866414T3
(pl)
*
|
2005-03-31 |
2012-10-31 |
Calando Pharmaceuticals Inc |
Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
|
|
WO2007002718A2
(en)
*
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and theraputic uses thereof
|
|
WO2007011819A2
(en)
*
|
2005-07-15 |
2007-01-25 |
The Penn State Research Foundation |
Ferritin as a therapeutic target in abnormal cells
|
|
WO2007014077A2
(en)
*
|
2005-07-21 |
2007-02-01 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the rho-a gene and uses thereof
|
|
EP2325315B1
(en)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
|
ES2385924T3
(es)
*
|
2006-02-02 |
2012-08-03 |
Allergan, Inc. |
Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
|
|
WO2007111998A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Novartis Ag |
Dsrna compositions and methods for treating hpv infection
|
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Eg5遺伝子発現の抑制のための組成物および方法
|
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
|
US7605251B2
(en)
|
2006-05-11 |
2009-10-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
US7888498B2
(en)
*
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
JP2010500011A
(ja)
|
2006-08-08 |
2010-01-07 |
ガンサー ハートマン |
5’リン酸オリゴヌクレオチドの構造および使用
|
|
WO2008026946A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
|
WO2008039937A2
(en)
*
|
2006-09-27 |
2008-04-03 |
Novarx |
Blocking of gene expression in eukaryotic cells
|
|
JP2010513354A
(ja)
|
2006-12-19 |
2010-04-30 |
ノヴォソム アクチェンゲゼルシャフト |
トランスフェクションエンハンサー要素を含む脂質および脂質集合体
|
|
WO2008086556A1
(en)
|
2007-01-16 |
2008-07-24 |
The University Of Queensland |
Method of inducing an immune response
|
|
US20080176958A1
(en)
|
2007-01-24 |
2008-07-24 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
|
PE20090064A1
(es)
*
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
JP5350360B2
(ja)
|
2007-03-29 |
2013-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
エボラ由来の遺伝子の発現を阻害するための組成物および方法
|
|
WO2008144365A2
(en)
*
|
2007-05-17 |
2008-11-27 |
Novartis Ag |
Method for making dry powder compositions containing ds-rna based on supercritical fluid technology
|
|
WO2009076400A2
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
NZ585784A
(en)
|
2007-12-13 |
2012-09-28 |
Alnylam Pharmaceuticals Inc |
siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
|
|
US8288525B2
(en)
*
|
2008-02-12 |
2012-10-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD45 gene
|
|
JP2009203173A
(ja)
*
|
2008-02-26 |
2009-09-10 |
Hokkaido Univ |
siRNA−ポリカチオン複合体を含有するイオントフォレーシス用組成物
|
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
|
BRPI0908737B1
(pt)
|
2008-03-19 |
2022-05-03 |
Circular Commitment Company |
Anticorpo, seu uso e método de diagnóstico de carcinoma hepatocelular
|
|
JP2011516065A
(ja)
|
2008-04-04 |
2011-05-26 |
カランド ファーマシューティカルズ, インコーポレイテッド |
Epas1阻害剤の組成物および使用
|
|
WO2009129465A2
(en)
|
2008-04-17 |
2009-10-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of xbp-1 gene
|
|
WO2009134405A2
(en)
*
|
2008-04-30 |
2009-11-05 |
Siemens Medical Solutions Usa, Inc. |
Novel substrate based pet imaging agents
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
US20110184046A1
(en)
|
2008-07-11 |
2011-07-28 |
Dinah Wen-Yee Sah |
Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
|
|
WO2010008562A2
(en)
*
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
|
WO2010017328A2
(en)
*
|
2008-08-06 |
2010-02-11 |
Rgo Biosciences Llc |
Cyclodextrin conjugates
|
|
ES2915692T3
(es)
*
|
2008-08-13 |
2022-06-24 |
California Inst Of Techn |
Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
|
|
US20100068737A1
(en)
*
|
2008-09-16 |
2010-03-18 |
University Of Tennessee Research Foundation |
Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
|
|
EP2166076A1
(en)
*
|
2008-09-23 |
2010-03-24 |
The Procter & Gamble Company |
Cleaning composition
|
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
EP2344638A1
(en)
|
2008-10-06 |
2011-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of an rna from west nile virus
|
|
EP2937418B1
(en)
|
2008-10-20 |
2017-10-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
EP2355848A2
(en)
*
|
2008-10-22 |
2011-08-17 |
Universität Zürich Prorektorat MNW |
Blockers of light, ltalpha1beta2 and ltalpha2beta1 or their receptor ltbetar for the prevention and treatment of chronic hepatitis and other liver diseases
|
|
ES2732504T3
(es)
|
2008-10-29 |
2019-11-22 |
Circular Commitment Company |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
|
EP2373382B1
(en)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
CA2753703A1
(en)
*
|
2009-03-04 |
2010-09-10 |
Hirofumi Takeuchi |
Nucleic acid complex and nucleic acid-delivering composition
|
|
CA2754043A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
WO2010111468A2
(en)
*
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
US8859516B2
(en)
|
2009-09-15 |
2014-10-14 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
IN2012DN02345A
(cg-RX-API-DMAC10.html)
|
2009-09-16 |
2015-08-21 |
Univ Duke |
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
JP5723378B2
(ja)
|
2009-11-03 |
2015-05-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスサイレチン(ttr)を阻害する脂質製剤化組成物及び方法
|
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
|
EP3578657B1
(en)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
EP3456827A3
(en)
|
2010-06-02 |
2019-05-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
JP2013223426A
(ja)
*
|
2010-08-12 |
2013-10-31 |
Chugai Pharmaceut Co Ltd |
Rrm2のアンタゴニストを有効成分として含有するc型肝炎治療剤
|
|
WO2012056441A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
Compositions and methods for specific cleavage of exogenous rna in a cell
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
US8501930B2
(en)
*
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
KR102104401B1
(ko)
|
2011-03-29 |
2020-04-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
WO2012174224A2
(en)
*
|
2011-06-17 |
2012-12-20 |
Calando Pharmaceuticals, Inc. |
Methods for administering nucleic acid-based therapeutics
|
|
CA2839573A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
EP2723351B1
(en)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP2723756B1
(en)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
|
EP2723861A4
(en)
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
|
UA118649C2
(uk)
|
2011-11-18 |
2019-02-25 |
Елнілем Фармасьютікалз, Інк. |
ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
|
BR112015013105B1
(pt)
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
|
US9132097B2
(en)
|
2013-03-01 |
2015-09-15 |
California Institute Of Technology |
Nanoparticles stabilized with nitrophenylboronic acid compositions
|
|
PT2970974T
(pt)
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
|
MX385871B
(es)
|
2013-10-02 |
2025-03-18 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
|
WO2015051318A1
(en)
|
2013-10-04 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
US9493552B2
(en)
|
2013-11-15 |
2016-11-15 |
China Synthetic Rubber Corporation |
Therapeutic biologic for treatment of hepatocellular carcinoma
|
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
|
EP3105331B1
(en)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
KR102410072B1
(ko)
|
2014-08-29 |
2022-06-20 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
TWI769565B
(zh)
|
2014-11-10 |
2022-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)iRNA組成物及其用途方法
|
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
BR112017021053A2
(en)
|
2015-04-13 |
2018-08-14 |
Alnylam Pharmaceuticals, Inc. |
angiopoietin type 3 (angpt13) irna compositions and methods of use thereof
|
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
EP3317323B1
(en)
|
2015-07-01 |
2021-05-26 |
California Institute of Technology |
Cationic mucic acid polymer-based delivery systems
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
LT3329002T
(lt)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals, Inc. |
Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
|
|
CN115957337A
(zh)
|
2015-08-07 |
2023-04-14 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
|
EP3340994A1
(en)
|
2015-08-25 |
2018-07-04 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
|
|
US10889813B2
(en)
|
2015-09-02 |
2021-01-12 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
IL308717A
(en)
|
2015-12-07 |
2024-01-01 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
WO2017111045A1
(en)
*
|
2015-12-25 |
2017-06-29 |
Sbi Biotech Co., Ltd. |
Tlr inhibitory oligonucleotides and their use
|
|
US9732303B2
(en)
|
2016-01-06 |
2017-08-15 |
The Procter & Gamble Company |
Microcapsules formed from phosphate esters and compositions containing same
|
|
US9730867B2
(en)
|
2016-01-06 |
2017-08-15 |
The Procter & Gamble Company |
Methods of forming a slurry with microcapsules formed from phosphate esters
|
|
US10154947B2
(en)
|
2016-01-06 |
2018-12-18 |
The Procter & Gamble Company |
Antiperspirant composition
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
TWI865997B
(zh)
|
2016-12-16 |
2024-12-11 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
|
|
US12447464B2
(en)
|
2016-12-22 |
2025-10-21 |
Duke University |
Polycationic microfibers and methods of using the same
|
|
EP3565596A4
(en)
|
2017-01-05 |
2020-12-16 |
Brown University |
PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
|
|
JP7325045B2
(ja)
|
2017-02-27 |
2023-08-14 |
カイロス セラピューティクス, インコーポレイテッド |
癌を処置する抗体コンストラクトおよび方法
|
|
WO2018195165A1
(en)
|
2017-04-18 |
2018-10-25 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
|
CN110809582B
(zh)
|
2017-05-01 |
2023-12-22 |
儿童医疗中心有限公司 |
涉及抗pd1抗体试剂的方法以及组合物
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
AU2018301829B2
(en)
|
2017-07-13 |
2024-08-01 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
|
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
EP3684931A1
(en)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
CA3078971A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
EP3710587A1
(en)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
WO2019126097A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
|
KR102083478B1
(ko)
*
|
2017-12-28 |
2020-04-28 |
한양대학교 산학협력단 |
Chi3l1 억제제를 유효성분으로 하는 암의 폐 전이 예방 또는 치료용 약학 조성물
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
US20190381188A1
(en)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
|
|
AR115960A1
(es)
|
2018-08-16 |
2021-03-17 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen lect2
|
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
|
PT4285929T
(pt)
|
2018-12-20 |
2026-01-02 |
Humabs Biomed Sa |
Terapêutica de combinação contra o vhb
|
|
US11510939B1
(en)
|
2019-04-19 |
2022-11-29 |
Apellis Pharmaceuticals, Inc. |
RNAs for complement inhibition
|
|
US12649792B2
(en)
|
2019-05-06 |
2026-06-09 |
Brown University |
Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Sepia Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
CA3158320A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
WO2021087036A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
IL292865A
(en)
|
2019-11-13 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
|
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
IL293824A
(en)
|
2019-12-13 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
|
|
CN115176007A
(zh)
|
2019-12-16 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法
|
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
PH12022552080A1
(en)
|
2020-02-10 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing vegf-a expression
|
|
CN115397989A
(zh)
|
2020-02-18 |
2022-11-25 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
|
MX2022011009A
(es)
|
2020-03-06 |
2022-10-07 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de ketohexocinasa (khk) y metodos de uso de las mismas.
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
EP4127134A4
(en)
|
2020-04-01 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
|
|
IL297121A
(en)
|
2020-04-06 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing myoc expression
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP7844347B2
(ja)
|
2020-04-27 |
2026-04-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法
|
|
MX2022013606A
(es)
|
2020-04-30 |
2023-01-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
AU2021292296A1
(en)
|
2020-06-18 |
2023-01-19 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
|
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
CA3200595A1
(en)
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor v (f5) irna compositions and methods of use thereof
|
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
AU2021414121A1
(en)
*
|
2020-12-29 |
2023-06-29 |
Suzhou Xinxin Biopharma Co., Ltd |
Compositions and associated methods for sustained-release of radioactive agents and their applications
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
US12649787B2
(en)
|
2021-01-15 |
2026-06-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-MFSD2A antibodies
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
|
CA3211059A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
BR112023017737A2
(pt)
|
2021-03-04 |
2023-10-03 |
Alnylam Pharmaceuticals Inc |
Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
CA3216106A1
(en)
|
2021-04-26 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
MX2023014008A
(es)
|
2021-05-27 |
2023-12-11 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2.
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
MX2023014168A
(es)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Marco de lectura abierto 72 del cromosoma humano 9 (c9orf72) composiciones de agente de arni y metodos de uso de este.
|
|
JP2024523000A
(ja)
|
2021-06-08 |
2024-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シュタルガルト病及び/又は網膜結合タンパク質4(rbp4)関連障害を治療又は予防するための組成物及び方法
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
JP2024528659A
(ja)
|
2021-07-19 |
2024-07-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
|
|
IL309897A
(en)
|
2021-07-21 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Target gene IRNA compositions associated with a metabolic disorder and methods of using them
|
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
3-ヒドロキシ-3-メチルグリタル-COAレダクターゼ(HMGCR)iRNA組成物およびその使用方法
|
|
AR126675A1
(es)
|
2021-08-03 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
|
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
|
CN118076737A
(zh)
|
2021-08-13 |
2024-05-24 |
阿尔尼拉姆医药品有限公司 |
因子XII(F12)iRNA组合物及其使用方法
|
|
TW202325311A
(zh)
|
2021-08-31 |
2023-07-01 |
美商艾拉倫製藥公司 |
誘導細胞死亡之DFFA樣效應子B (CIDEB) iRNA組合物及其使用方法
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分(C3)をサイレンシングするためのiRNA組成物および方法
|
|
JP2024535888A
(ja)
|
2021-09-20 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
インヒビンサブユニットベータe(inhbe)モジュレーター組成物およびその使用方法
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
EP4416284A1
(en)
|
2021-10-15 |
2024-08-21 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
AR127477A1
(es)
|
2021-10-29 |
2024-01-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
|
|
EP4423272A2
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
CN116515102B
(zh)
*
|
2022-01-21 |
2025-04-18 |
苏州万维生命科学技术有限公司 |
星型β-抗菌糖肽、其制备方法及应用
|
|
WO2023138211A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
苏州万维生命科学技术有限公司 |
星型β-抗菌糖肽、其制备方法及应用
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
KR20250022763A
(ko)
|
2022-06-10 |
2025-02-17 |
캠프4 테라퓨틱스 코포레이션 |
조절 rna를 표적으로 하는 안티센스 올리고뉴클레오타이드를 사용하여 프로그래뉼린 발현을 조절하는 방법
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
CN119907856A
(zh)
|
2022-09-15 |
2025-04-29 |
阿尔尼拉姆医药品有限公司 |
第13型17β-羟基类固醇脱氢酶(HSD17B13)iRNA组合物及其使用方法
|
|
EP4627084A1
(en)
|
2022-12-01 |
2025-10-08 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
IL322261A
(en)
|
2023-02-09 |
2025-09-01 |
Alnylam Pharmaceuticals Inc |
Reverser molecules and methods of using them
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
EP4743577A1
(en)
|
2023-07-13 |
2026-05-20 |
Korro Bio, Inc. |
RNA EDITING OLIGONUCLEOTIDES AND THEIR USES
|
|
EP4754255A1
(en)
|
2023-08-04 |
2026-06-10 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
AU2024348221A1
(en)
|
2023-09-27 |
2026-04-30 |
Judo Bio Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
EP4784753A2
(en)
|
2023-09-27 |
2026-08-05 |
Judo Bio Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
EP4784172A1
(en)
|
2023-09-27 |
2026-08-05 |
Judo Bio Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025255388A1
(en)
|
2024-06-05 |
2025-12-11 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2026136379A1
(en)
|
2024-12-17 |
2026-06-25 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2026151811A1
(en)
|
2025-01-07 |
2026-07-16 |
Camp4 Therapeutics Corporation |
Compositions and methods for treating urea cycle disorders
|